Clinical trials: Intravenous Infusions
Autoimmune Diseases
A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease
The goal of this clinical trial is to assess the safety and tolerability profile of belantamab. The study will also assess how the levels of belantamab change over time and body's reaction to it in participants with stable but…
- Trial name
- NCT06413511
- Testing
- Belantamab
- Sponsor
- GlaxoSmithKline
Infiltration, Extravasation
Monitoring the Peripheral Intravenous Infusion Site for Infiltration and Extravasation
The purpose of this study to to monitor the peripheral intravenous (PIV) site on subjects receiving continuous IV fluids for infiltration and extravasation events.
- Conditions
- Infiltration, Extravasation, IV Infiltration, IV Extravasation
- Trial name
- NCT01476293
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- ivWatch, LLC
Acute Myeloid Leukemia
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
The primary objectives of this study are to evaluate the safety and tolerability of emerfetamab in adults with relapsed/refractory acute myeloid leukemia (AML) and to estimate the maximum tolerated dose (MTD) and/or a…
- Trial name
- NCT03224819
- Testing
- Emerfetamab
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 46 people
- Sponsor
- Amgen
Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB)
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
The goal of this clinical trial is to assess safety and efficacy of systemic injection of allogenic NK cells in patients with refractory/recurrent high-risk neuroblastoma.
- Conditions
- Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB), Neuroblastoma in Children
- Trial name
- NCT06674265
- Testing
- Allogenic NK cells infusion
- Where
- Iran
- Volunteers
- 10 people
- Sponsor
- Marzieh Ebrahimi
Biological Availability
Pharmacokinetics of Fentanyl Following Intravenous and Oral Routes of Administration in Healthy Volunteers
The purpose of the study is to compare the pharmacokinetics of fentanyl following i.v. and oral administration in healthy volunteers, and to assess the bioavailability of fentanyl following oral administration.
- Trial name
- NCT00714558
- Testing
- Fentanyl citrate; Naltrexone; Naloxone
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Alza Corporation, DE, USA
Bacteremia Caused by Gram-Negative Bacteria, Bacterial Pneumonia
A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection
This is a retrospective, observational, post-marketing study to evaluate the clinical response, microbiological response, mortality, and safety of intravenous polymyxin B and colistin methanesulfonate in patients with…
- Trial name
- NCT06966284
- Where
- Taiwan
- Volunteers
- 480 people
- Sponsor
- TTY Biopharm
Multiple Myeloma
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
RATIONALE: Monoclonal antibodies, such as BB-10901, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- IMGN901 (NCT00346255)
- Testing
- BB-10901
- Where
- 8 sites in United States, Argentina
- Volunteers
- 37 people
- Sponsor
- ImmunoGen, Inc.
Breast Cancer
A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers
This is a double-blind, comparative, randomized phase I study comparing pharmacokinetics, safety and immunogenicity profiles of a biosimilar pertuzumab (BCD-178) and Perjeta after a single intravenous infusion in healthy male…
- Trial name
- NCT05738993
- Testing
- BCD-178, Perjeta
- Where
- 2 sites in Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Biocad
Arrhythmia
A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients
Medical Products Agency
- Trial name
- NCT01396226
- Testing
- AZD2927
- Where
- 5 sites in Norway, Sweden
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
- Conditions
- T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified
- Trial name
- NCT04234048
- Testing
- Fenretinide
- Where
- 10 sites in United States
- Volunteers
- 46 people
- Sponsor
- SciTech Development, Inc.
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years
Researchers are looking for a better way to treat people who have acute venous and arterial thrombotic and thromboembolic events. These are severe medical problems due to blood clots forming in and blocking blood vessels.
- Trial name
- NCT06562985
- Testing
- BAY3018250 Dose 1, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Bayer
End Stage Renal Disease
Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis
The purpose of this study is to assess the Aranesp® dose administered intravenously (IV) once weekly to maintain hemoglobin (Hgb) levels in hemodialysis subjects who are either recombinant human erythropoietin (rHuEPO) naïve or…
- Trial name
- NCT00117104
- Testing
- Aranesp®
- Sponsor
- Amgen
Cancer
Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma
This is a Phase 1 clinical trial examining the safety, pharmacokinetics and pharmacodynamics of escalating doses of the vascular disrupting agent NPI-2358 in patients with refractory solid tumors or lymphoma.
- Trial name
- NCT00322608
- Testing
- NPI-2358
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Nereus Pharmaceuticals, Inc.
Diagnostic Imaging
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-7548 in patients with cancer.
- Trial name
- NCT01205321
- Testing
- Bombesin (68Ga) labeled (BAY86-7548)
- Where
- 3 sites in Finland, Germany and 1 more
- Volunteers
- 19 people
- Sponsor
- Lantheus Biosciences Ltd.
Healthy Volunteer
A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers
The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.
- Trial name
- NCT07413133
- Testing
- ABBV-8736
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AbbVie
Neoplasm Malignant
A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification
Primary Objective: To determine objective response rate (ORR). Secondary Objectives: To assess duration of response (DR), progression free survival (PFS) and overall survival (OS). To evaluate global safety profile.
- Trial name
- NCT02435121
- Testing
- SAR125844
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- Sanofi
Rheumatoid Arthritis Aggravated
Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients
Phase Ib/IIa clinical trial of a new medicinal product of the somatic cell therapy class (eASCs). This study is designed as a multicenter, single blind, fixed dose escalation, with three treatment groups, controlled with placebo…
- Trial name
- NCT01663116
- Testing
- Stem cells
- Where
- 23 sites in Spain
- Volunteers
- 53 people
- Sponsor
- Tigenix S.A.U.
Metastatic Melanoma
A Study of Tasisulam in Treating Participants With Malignant Melanoma
The primary purpose of this study is to determine the objective response rate (complete and partial response) for participants who receive tasisulam after one prior systemic treatment for unresectable or metastatic melanoma.
- Trial name
- NCT00383292
- Testing
- tasisulam
- Where
- 13 sites in United States, Australia
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Acute, Post-operative Pain
Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427
This randomized, double-blind, placebo controlled, study will be conducted to evaluate the safety, tolerability, and pharmacokinetics of ST-2427.
- Trial name
- NCT04475198
- Testing
- ST-2427
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- SiteOne Therapeutics, Inc.
Rheumatoid Arthritis
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis
This randomized, double-blind, parallel group study compares the efficacy and safety of subcutaneous (sc) versus intravenous (iv) administration of tocilizumab in participants with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT01194414
- Testing
- tocilizumab SC, tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
- Where
- 216 sites in United States, Argentina and 24 more
- Volunteers
- 1,262 people
- Sponsor
- Hoffmann-La Roche